PEPG — PepGen Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1835597 ·
Last close
$3.88
Market Cap
$365.73M
52W High
$7.80
52W Low
$1.31
ADV30
5,789,839
Next earnings
2026-11-10
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -20,383,000 -19,391,000 127,777,000 21,957,000 24,711,000
Jun 2026 0 — -18,939,000 -17,812,000 141,397,000 22,764,000 21,864,000
Mar 2026 0 — -18,942,000 -17,763,000 156,295,000 42,150,000 22,315,000
Dec 2025 0 — -19,705,000 -18,340,000 173,907,000 60,514,000 26,463,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-63,252,000
Investing CF
$-58,761,000
Financing CF
$1,196,000
CapEx
$-265,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-416,084,000
Inventory
—
Receivables
—
ST Investments
$82,848,000
EBIT TTM
$-77,969,000
Pretax Income TTM
$-73,213,000
Interest Exp TTM
—
Analysts
8

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -93,612,000 -89,655,000 173,907,000 26,463,000 147,444,000 -81,635,000
Dec 2024 0 -97,739,000 -89,981,000 150,883,000 32,263,000 118,620,000 -82,372,000
Dec 2023 0 -84,766,000 -78,626,000 143,052,000 34,631,000 108,421,000 -68,997,000
Dec 2022 0 -68,301,000 -69,104,000 217,440,000 37,809,000 179,631,000 -59,265,000

TTM Snapshot

Revenues TTM
$4,396,000
NetIncome TTM
$-71,941,000
OpCashFlow TTM
—
Assets (Latest)
$141,397,000
Forward EPS
$-1.17

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $3.83 · call volume: 64 · put volume: 239
Expected Move to 2027-02-19: ±$2.62 (68.41%) — implied range $1.21 – $6.45 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CYDY CytoDyn Inc. $366.64M $0.25 —
SPRY ARS Pharmaceuticals, Inc. $366.93M $3.65 —
PBYI PUMA BIOTECHNOLOGY, INC. $369.13M $7.14 —
NIKA NIKA PHARMACEUTICALS, INC $369.14M $0.35 —
CRMD CorMedix Inc. $371.44M $4.67 —

News headlines (Yahoo Finance, 1h cache)

PepGen (PEPG) Stock Sees Fair Value Lift After Encouraging EDODM1 Analyst Reactions
2026-11-13 01:16 · Yahoo
PepGen Announces Pricing of $125 Million Public Offering
2026-11-12 03:22 · Yahoo
PepGen’s stock skyrockets on record-breaking DM1 trial data
2026-11-11 18:19 · Yahoo
PepGen soars on promising early data for muscular dystrophy drug
2026-11-10 21:48 · Yahoo
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
2026-11-10 21:23 · Yahoo
PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure.
2026-11-10 18:48 · Yahoo
PepGen Stock Doubles in One Session - Here's Why
2026-11-10 18:47 · Yahoo
PepGen Reports Phase 2 Myotonic Dystrophy Trial Results and $104.8 Million Cash Position
2026-11-10 15:56 · Yahoo
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-10 12:05 · Yahoo
PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
2026-11-10 12:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.